Zydus Lifesciences gains on getting USFDA`s final approval for Azithromycin Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Zydus Lifesciences is currently trading at Rs. 497.65, up by 1.15 points or 0.23% from its previous closing of Rs. 496.50 on the BSE.
The scrip opened at Rs. 499.65 and has touched a high and low of Rs. 501.35 and Rs. 493.60 respectively. So far 39687 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 501.35 on 11-Apr-2023 and a 52 week low of Rs. 319.40 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 501.35 and Rs. 486.05 respectively. The current market cap of the company is Rs. 50453.32 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 17.02% and 8.00% respectively
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Azithromycin Tablets USP, 500 mg (USRLD: Zithromax Tablets).
Azithromycin is indicated to treat certain bacterial infections such as bronchitis, pneumonia, sexually transmitted diseases (STD), infections of the ears, lungs, sinuses, skin, throat, and reproductive organs. The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).
Azithromycin Tablets USP, 500 mg had annual sales of $20 million in the United States (IQVIA MAT Feb. 2023). The group now has 360 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
